Kraig Biocraft Laboratories has established an immortalized silk gland cell line demonstrating strong proliferative capacity, stable serial passaging, and robust long-term in vitro viability. This development provides a highly versatile, next-generation biotechnology platform for scalable industrial bioprocessing, with early testing showing exceptionally strong recombinant protein expression capabilities that could integrate with conventional infrastructure. The technology expands commercial potential beyond spider silk fibers into new applications supporting the manufacturing of therapeutics, vaccines, active proteins, and advanced biomaterials.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
